Related Experiment Video

Updated: Apr 18, 2026

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

14.2K

[Fatal agranulocytosis after metamizole reexposure]

Evmarie Zeiner1, Lea S Blaser2, Kai Tisljar1

  • 1Klinik für Intensivmedizin, Universitätsspital Basel.

Praxis
|January 29, 2015
PubMed

Insights

Dipyrone (metamizole) can cause severe agranulocytosis, a dangerous drop in white blood cells. Re-exposure to dipyrone carries significant risks, even after a prior adverse event, as seen in a fatal case of septic shock.

Area of Science:

  • Pharmacology
  • Hematology
  • Clinical Medicine

Background:

  • Dipyrone (metamizole) is a widely used analgesic and antipyretic.
  • Agranulocytosis is a rare but life-threatening adverse drug reaction.
  • Previous exposure to dipyrone can increase the risk of subsequent agranulocytosis.

Observation:

  • A 63-year-old man developed fatal septic shock due to dipyrone-induced agranulocytosis.
  • The patient had a history of agranulocytosis following dipyrone exposure 18 months earlier.
  • This case highlights the severe consequences of dipyrone re-exposure.

Findings:

  • Dipyrone-induced agranulocytosis can be rapidly fatal.
  • Re-challenging patients with dipyrone after a prior episode of agranulocytosis is extremely hazardous.
  • Effective patient-physician communication is crucial for preventing adverse drug events.

Implications:

  • Clinicians must be vigilant about the risk of dipyrone-induced agranulocytosis.
  • Patient history of adverse reactions to dipyrone should be carefully documented and communicated.
  • Enhanced awareness and communication strategies are needed to mitigate risks associated with dipyrone use.
Keywords:
AgranulozytoseMetamizolSeptischer Schockagranulozytosismetamizoleseptic shock

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.7K
MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data07:17

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

976

Related Concept Videos

Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
198
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
174
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
181
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
226
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.5K